文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

IPSS-M风险与特定性相关体细胞突变预测低危骨髓增生异常综合征对促红细胞生成素治疗的反应:构建新评分

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.
PubMed 文献 · Blood · 2025-01-01

该研究在535例低危骨髓增生异常综合征(LR-MDS)欧洲队列中,用靶向二代测序计算IPSS-M评分,结合血清促红细胞生成素和输血依赖构建ESA-PSS-M评分预测ESA反应,并在223例外部队列验证;男性STAG2突变与ESA抵抗显著相关。

要点

  • IPSS-M评分联合血清促红细胞生成素和输血依赖可提升ESA反应预测能力(AUC 0.71 vs 0.63,P=0.0004)。
  • 基于上述三变量构建ESA-PSS-M评分(特异性76%,敏感性57%),并在外部队列验证。
  • 男性LR-MDS中X连锁STAG2突变与ESA抵抗显著相关(OR 0.13,P=0.003)。

核心结论

  • 据作者所知,这是首个基于大型多中心队列的研究,提示IPSS-M评分与性别特异性突变的整合可刻画ESA抵抗并指导贫血性LR-MDS的一线治疗选择(即ESA vs 罗特西普)。

研究设计与样本

  • 欧洲多中心队列研究,纳入535例LR-MDS患者,采用靶向二代测序计算IPSS-M评分。
  • 外部验证队列纳入223例LR-MDS患者。

主要发现

  • 将IPSS-M评分纳入血清促红细胞生成素和输血依赖两个已知变量后,预测ESA反应的能力提升(AUC 0.71 vs 0.63,P=0.0004)。
  • 基于血清促红细胞生成素、IPSS-M评分和输血依赖构建ESA-PSS-M评分(特异性76%,敏感性57%),并在外部队列验证。
  • 尽管IPSS-M评分有影响,但无单个突变基因与ESA反应相关。
  • 按出生性别分层后,男性LR-MDS中X连锁STAG2基因突变与ESA抵抗显著相关(OR 0.13,P=0.003)。

关键数值与推荐

  • ESA-PSS-M评分公式:-0.05×[血清促红细胞生成素 U/L] -4.5×[IPSS-M评分] -5×[输血依赖(是=1;否=0)],特异性76%,敏感性57%。
  • IPSS-M评分联合血清促红细胞生成素和输血依赖预测ESA反应的AUC为0.71,高于未联合时的0.63(P=0.0004)。
  • 男性LR-MDS中STAG2突变与ESA抵抗的OR为0.13(P=0.003)。

临床怎么用

  • 作者认为,IPSS-M评分与性别特异性突变的整合可刻画ESA抵抗并指导贫血性LR-MDS的一线治疗选择(即ESA vs 罗特西普)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired somatic mutations are incorporated in the classification and prognosis of myelodysplastic syndromes/neoplasms (MDSs). However, the predictive role of molecular features in MDS needs to be elucidated, especially in the lower-risk subtypes (LR-MDS), where treatment has become heterogeneous and predictive biomarkers are lacking. In this study, we investigated genetic markers associated with erythropoiesis-stimulating agents (ESAs) response in LR-MDS. A European cohort of 535 patients with LR-MDS was analyzed using targeted next-generation sequencing (t-NGS) to calculate molecular prognostic scores (International Prognostic Scoring System, molecular [IPSS-M]). The integration of IPSS-M score among the 2 known variables, serum erythropoietin (sEPO) and transfusion dependence (TD), refined the capability to predict response (area under the curve [AUC], 0.71 vs 0.63, P = .0004). Based on these 3 variables, a molecular predictive score, which we named ESA-PSS-M (-0.05 × [sEPO U/L] -4.5 × [IPSS-M score] -5 × [TD (yes = 1; no = 0)]; specificity 76%; sensitivity 57%), was generated and validated in an external cohort (n = 223 patients with LR-MDS). Despite the impact of IPSS-M score, no single mutated gene was linked to ESA response; however, when we stratified cases by sex at birth, the X-linked STAG2 gene mutations were significantly associated with ESA resistance in males with LR-MDS (odds ratio, 0.13; P = .003). To our knowledge, this is the first study based on a large multicenter cohort of patients suggesting that the integration of IPSS-M score and sex-specific mutations can characterize ESA resistance and guide first-line (1L) therapeutic choices for anemic LR-MDS (ie, ESAs vs luspatercept).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Raddi MG, Park S, Fontenay M, et al. IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score. Blood. 2025. PMID: 40561337. doi:10.1182/blood.2024027540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。